WI-ROCKWELL-AUTOMATION
20.4.2021 09:32:07 CEST | Business Wire | Press release
Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, and Comau, a global leader in industrial automation and robot manufacturer, announced today that they are joining forces to give businesses worldwide vital tools to maximize manufacturing efficiencies through unified robot control solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210420005326/en/
“Industrial companies are looking for efficient ways to integrate robotics into their operations for process optimization and agility,” said Rockwell Automation Chairman and CEO Blake Moret. “Rockwell Automation’s collaboration with Comau will simplify programming and lifecycle management, accelerating time to value for our customers.”
Moret said this expansion of robotic applications is rooted in Rockwell’s broader strategy to help industrial companies save time and improve performance with unified robot control, ultimately providing long-term value for their business. The partnership is a collaborative development and selling model that offers the unified robot control product to both companies’ customers.
“Comau’s robotics and industrial automation expertise, as well as its reputation for high performance, reliability, and quality, combined with Rockwell Automation’s global capabilities and experience in automated material handling, food and beverage, household and personal care, and life sciences, gives customers the incremental value of an integrated robot solution,” said Comau CEO Paolo Carmassi. “Comau is eager to work with such an important partner that has a market-leading global footprint in all industries.”
Engineers will now be able to program their entire machine in one environment, including Comau robot arms directly controlled through Rockwell Automation’s Logix-based controllers. Rockwell Automation’s Studio 5000® automation system design software provides relief from the time-consuming and often difficult task of trying to coordinate traditionally separate machine control and robot systems to work together using two different software tools.
Machine builders, system integrators, and others will gain development and deployment efficiencies through the use of digital engineering tools like Rockwell’s Emulate3D digital twin software, which creates digital models of production lines, auto-generates machine control code, and has built-in capabilities for Comau robots.
The combined Rockwell and Comau solutions will also offer benefits beyond enhanced integration. For example, end users can use analytics and digital twin tools to gain deeper insights into machine performance and potential production optimization. They can also use safety and security solutions to reduce business risks.
Operators on the manufacturing floor who use Rockwell’s FactoryTalk® software suite will benefit from being able to see both line and robot control systems on a single interface. In-plant and remote technicians will only need to learn and maintain one architecture to monitor both systems. They can also leverage Rockwell’s augmented reality (AR) tools to improve lifecycle and service cycle maintenance.
Automazioni Industriali Capitanio, a recognized system integrator, designs, manufactures, and commissions automation systems for the metals industry and is an early adopter of the joint solution. Marco Capitanio, managing director of AIC, said the Rockwell-Comau collaboration allows the company to offer a seamless robot solution for customers, which he sees as a key advantage for a machine builder.
“We value the simple and flexible programming environment, complete access to robot supervision and diagnostic parameters, and the ability to leverage existing automation panels and standard control devices,” Capitanio said.
Rockwell products and technology that will be key to robotics integration include the following:
- Allen-Bradley ControlLogix® control systems
- Kinetix® 5700 servo drive platform
- Studio 5000® automation system design software
- FactoryTalk® View human machine interface (HMI) software
- FactoryTalk® InnovationSuite™, powered by PTC digital transformation software suite
- Emulate3D™ digital twin software
- PTC Vuforia AR tools for remote collaboration and information capture
Comau’s comprehensive robot range meets the needs of a wide variety of industries, from automotive to logistics, food and beverage, and packaging, just to name a few. It includes more than 40 different industrial robotic arms, with load capacities from 3 to 650 KG.
About Comau
Comau, a member of Stellantis, is a worldwide leader in delivering advanced industrial automation products, and systems. With over 45 years of experience and a strong presence within every major industrial country, Comau is helping manufacturers of all sizes in almost any industry experience higher quality, increased productivity, faster time-to-market, and lower overall costs. Headquartered in Turin, Italy, Comau has an international network of 7 innovation centers, 5 digital hubs, 8 manufacturing plants that span 14 countries and employ more than 9,000 people. For more information, visit www.comau.com .
About Rockwell Automation
Rockwell Automation, Inc. (NYSE: ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 23,500 problem solvers dedicated to our customers in more than 100 countries. To learn more about how we are bringing the Connected Enterprise to life across industrial enterprises, visit www.rockwellautomation.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005326/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom